Amendments to the Claims:

The following claims will replace all prior versions of the claims in this application (in the unlikely event that no claims follow herein, the previously pending claims will remain):

- 1-59. (Cancelled).
- 60. (New) A method of treating a mammal to bring about a weight reduction or reduction in obesity, said method comprising administering to the mammal in need of such treatment a therapeutically effective dosage of a lipid mobilizing agent which is a $Zn-\alpha_2$ -glycoprotein, the polypeptide moiety thereof having the sequence as shown in SEQ ID NO:1.
- 61. (New) A pharmaceutical composition in unit dosage form suitable for oral, rectal, topical or parenteral administration and comprising:
 - a pharmaceutically acceptable carrier, diluent or excipient; and
- a pharmacologically effective amount of biologically active lipid mobilizing agent which is a $Zn-\alpha_2$ -glycoprotein, the polypeptide moiety thereof having the sequence as shown in SEQ ID NO:1.
- 62. (New) A pharmaceutical composition as claimed in claim 61, which is an injectable formulation incorporating a carrier in the form of a pharmaceutically acceptable injection vehicle.
- 63. (New) A method of treating a mammal to bring about a weight reduction or reduction in obesity, said method comprising administering to the mammal in need of such treatment a therapeutically effective dosage of a lipid mobilizing agent having an apparent molecular mass of greater than about 6 kDa, as determined by gel exclusion chromatography, and which is obtained by digesting $Zn-\alpha_2$ -glycoprotein, the polypeptide moiety of which has the sequence shown in SEQ ID NO:1, with the enzyme trypsin.

Application No. <u>09/701,463</u>

Amendment dated January 21, 2004

Page 3

64. (New) A pharmaceutical composition in unit dosage form suitable for oral, rectal, topical or parenteral administration and comprising:

a pharmaceutically acceptable carrier, diluent or excipient; and a pharmacologically effective amount of biologically active lipid mobilizing agent having an apparent molecular mass of greater than about 6 kDa, as determined by gel exclusion chromatography, and which is obtained by digesting Zn-α₂-glycoprotein, the polypeptide moiety of which has the sequence shown in SEQ ID NO:1, with the enzyme trypsin.

- 65. (New) A pharmaceutical composition as claimed in claim 64, which is an injectable formulation incorporating a carrier in the form of a pharmaceutically acceptable injection vehicle.
- 66. (New) A pharmaceutical composition as claimed in claim 64, wherein the biologically active lipid mobilizing agent has an apparent molecular mass of about 7 kDa.